In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merck gets ex- N. American rights to Cardiome's oral vernakalant; later gains WW rights; deal ends

Executive Summary

Cardiovascular therapeutics developer Cardiome Pharma has granted Merck & Co. exclusive rights to its oral version of vernakalant, a Phase III drug candidate for atrial fibrillation (AF). The Merck Sharp & Dohme subsidiary received a global license (excluding the US, Canada, and Mexico) to the intravenous formulation.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • R&D and Marketing (Licensing)

Related Companies